NCT07598214

Brief Summary

The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
6mo left

Started Feb 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Feb 2025Dec 2026

Study Start

First participant enrolled

February 3, 2025

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

February 1, 2026

Completed
4 months until next milestone

First Posted

Study publicly available on registry

May 20, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 3, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 3, 2026

Last Updated

May 20, 2026

Status Verified

May 1, 2026

Enrollment Period

1.7 years

First QC Date

February 1, 2026

Last Update Submit

May 17, 2026

Conditions

Cancer Patients

Outcome Measures

Primary Outcomes (2)

  • serum creatinine level

    Serum creatinine will be measured in mg/dl every 2 weeks during the study period.

    6 months following treatment

  • blood urea level

    blood urea levels will be measured in mg/dl every 2 weeks during the study period.

    6 months following treatment

Secondary Outcomes (1)

  • hemoglobin level

    6 months following treatment

Study Arms (1)

control

EXPERIMENTAL

patients will take no intervention

Combination Product: diosmin/hesperdin

Interventions

diosmin/hesperdinCOMBINATION_PRODUCT

combination of Diosmin and Hesperidin

control

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.

You may not qualify if:

  • History of allergic reactions attributed to drugs in the study.
  • Pregnant women.
  • Life expectancy less than 6 months
  • Inability or unwillingness to comply with research protocols.
  • Cancer patients with impaired renal function (creatinine clearance \< 50 mL/min)
  • Preexisting hearing loss.
  • Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine

Banī Suwayf, 0000, Egypt

RECRUITING

MeSH Terms

Interventions

Diosmin

Intervention Hierarchy (Ancestors)

FlavonesFlavonoidsChromonesBenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • marwa mohsen

    clinical pharmacy department, Beni Suef University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

marwa mohsen, PhD

CONTACT

01202203223marwa.mohsen@pharm.bsu.edu.eg

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

February 1, 2026

First Posted

May 20, 2026

Study Start

February 3, 2025

Primary Completion (Estimated)

November 3, 2026

Study Completion (Estimated)

December 3, 2026

Last Updated

May 20, 2026

Record last verified: 2026-05

Locations

EG(1)